AIM
NTGN

Alambic Investment Management’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

Alambic Investment Management’s Portfolio NTGN Stock Details NTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-15,200
Closed -$18K – 309
2019
Q4 		$18K Sell
15,200
-10,600
-41% -$16.9K 0.02% 278
2019
Q3 		$44K Buy
+25,800
New +$78.5K 0.03% 287

Other funds holding NTGN

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Athanor Capital New York $24.6M AUM 2.49% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Alambic Investment Management's NTGN Position: Q1 2020 in Review

Alambic Investment Management sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q1 2020, closing a stake of 15,200 shares — an estimated $18K sold.

Alambic Investment Management first reported a position in NTGN in Q3 2019 and held it in 2 quarters. The position peaked at $44K in Q3 2019. 43 funds tracked by Wall St. Rank hold NTGN as of Q1 2020.

  • Alambic Investment Management reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Alambic Investment Management sold 15,200 Neon Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $18K.
  • Alambic Investment Management first reported a position in Neon Therapeutics, Inc. Common Stock in Q3 2019 and held it in 2 quarters.
  • Alambic Investment Management's Neon Therapeutics, Inc. Common Stock position peaked at $44K in Q3 2019.
  • 43 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Alambic Investment Management's 13F filing for Q1 2020, filed 11 May 2020.